[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.234.140. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Jick  HKaye  JAJick  SS Antidepressants and the risk of suicidal behaviors.  JAMA 2004;292338- 343PubMedGoogle ScholarCrossref
2.
Hyman  SENestler  EJ Initiation and adaptation: a paradigm for understanding psychotropic drug action.  Am J Psychiatry 1996;153151- 162PubMedGoogle Scholar
3.
Vetulani  JSulser  F Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain.  Nature 1975;257495- 496PubMedGoogle ScholarCrossref
4.
Manji  HKQuiroz  JASporn  JPayne  JLDenicoff  KGray  NAZarate  CA  JrCharney  DS Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression.  Biol Psychiatry 2003;53707- 742PubMedGoogle ScholarCrossref
5.
Skolnick  PLegutko  BLi  XBymaster  FP Current perspectives on the development of non-biogenic amine-based antidepressants.  Pharmacol Res 2001;43411- 423PubMedGoogle ScholarCrossref
6.
Coyle  JTDuman  RS Finding the intracellular signaling pathways affected by mood disorder treatments.  Neuron 2003;38157- 160PubMedGoogle ScholarCrossref
7.
Nestler  EJBarrot  MDiLeone  RJEisch  AJGold  SJMonteggia  LM Neurobiology of depression.  Neuron 2002;3413- 25PubMedGoogle ScholarCrossref
8.
Skolnick  P Antidepressants for the new millennium.  Eur J Pharmacol 1999;37531- 40PubMedGoogle ScholarCrossref
9.
Skolnick  PLayer  RTPopik  PNowak  GPaul  IATrullas  R Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression.  Pharmacopsychiatry 1996;2923- 26PubMedGoogle ScholarCrossref
10.
Skolnick  P Modulation of glutamate receptors: strategies for the development of novel antidepressants.  Amino Acids 2002;23153- 159PubMedGoogle ScholarCrossref
11.
Zarate  CA  JrDu  JQuiroz  JGray  NADenicoff  KDSingh  JCharney  DSManji  HK Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system.  Ann N Y Acad Sci 2003;1003273- 291PubMedGoogle ScholarCrossref
12.
Layer  RTPopik  POlds  TSkolnick  P Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715).  Pharmacol Biochem Behav 1995;52621- 627PubMedGoogle ScholarCrossref
13.
Meloni  DGambarana  CDe Montis  MGDal Pra  PTaddei  ITagliamonte  A Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats.  Pharmacol Biochem Behav 1993;46423- 426PubMedGoogle ScholarCrossref
14.
Moryl  EDanysz  WQuack  G Potential antidepressive properties of amantadine, memantine and bifemelane.  Pharmacol Toxicol 1993;72394- 397PubMedGoogle ScholarCrossref
15.
Papp  MMoryl  E Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression.  Eur J Pharmacol 1994;2631- 7PubMedGoogle ScholarCrossref
16.
Przegalinski  ETatarczynska  EDeren-Wesolek  AChojnacka-Wojcik  E Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist.  Neuropharmacology 1997;3631- 37PubMedGoogle ScholarCrossref
17.
Trullas  RSkolnick  P Functional antagonists at the NMDA receptor complex exhibit antidepressant actions.  Eur J Pharmacol 1990;1851- 10PubMedGoogle ScholarCrossref
18.
Yilmaz  ASchulz  DAksoy  ACanbeyli  R Prolonged effect of an anesthetic dose of ketamine on behavioral despair.  Pharmacol Biochem Behav 2002;71341- 344PubMedGoogle ScholarCrossref
19.
Boyer  PASkolnick  PFossom  LH Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain: a quantitative in situ hybridization study.  J Mol Neurosci 1998;10219- 233PubMedGoogle ScholarCrossref
20.
Krystal  JHSanacora  GBlumberg  HAnand  ACharney  DSMarek  GEpperson  CNGoddard  AMason  GF Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.  Mol Psychiatry 2002;7 ((suppl 1)) S71- S80PubMedGoogle ScholarCrossref
21.
Zarate  CAQuiroz  JPayne  JManji  HK Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders.  Psychopharmacol Bull 2002;3635- 83PubMedGoogle Scholar
22.
Sanacora  GGueorguieva  REpperson  CNWu  YTAppel  MRothman  DLKrystal  JHMason  GF Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression.  Arch Gen Psychiatry 2004;61705- 713PubMedGoogle ScholarCrossref
23.
Calabrese  JRBowden  CLSachs  GSAscher  JAMonaghan  ERudd  GD A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression: Lamictal 602 Study Group.  J Clin Psychiatry 1999;6079- 88PubMedGoogle ScholarCrossref
24.
Zarate  CAJPayne  JLQuiroz  JSporn  JDenicoff  KKLuckenbaugh  DCharney  DSManji  HK An open-label trial of riluzole in treatment-resistant major depression.  Am J Psychiatry 2004;161171- 174PubMedGoogle ScholarCrossref
25.
Zarate  CAJQuiroz  JASingh  JBDenicoff  KDDe Jesus  GLuckenbaugh  DACharney  DSManji  HK An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.  Biol Psychiatry 2005;57430- 432PubMedGoogle ScholarCrossref
26.
Berman  RMCappiello  AAnand  AOren  DAHeninger  GRCharney  DSKrystal  JH Antidepressant effects of ketamine in depressed patients.  Biol Psychiatry 2000;47351- 354PubMedGoogle ScholarCrossref
27.
First  MBSpitzer  RLGibbon  MWilliams  AR Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P).  New York New York State Psychiatric Institute, Biometrics Research2001;
28.
Hamilton  M A rating scale for depression.  J Neurol Neurosurg Psychiatry 1960;2356- 62PubMedGoogle ScholarCrossref
29.
Sackeim  HA The definition and meaning of treatment-resistant depression.  J Clin Psychiatry 2001;62 ((suppl 16)) 10- 17PubMedGoogle Scholar
30.
Beck  ATBeamesderfer  A Assessment of depression: the depression inventory.  Mod Probl Pharmacopsychiatry 1974;7151- 169PubMedGoogle Scholar
31.
Overall  JEGorham  DR The Brief Psychiatric Rating Scale.  Psychol Rep 1962;10799- 812Google ScholarCrossref
32.
Young  RCBiggs  JTZiegler  VEMeyer  DA A rating scale for mania: reliability, validity and sensitivity.  Br J Psychiatry 1978;133429- 435PubMedGoogle ScholarCrossref
33.
Aitken  RC Measurement of feelings using visual analogue scales.  Proc R Soc Med 1969;62989- 993PubMedGoogle Scholar
34.
Frank  EPrien  RFJarrett  RBKeller  MBKupfer  DJLavori  PWRush  AJWeissman  MM Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence.  Arch Gen Psychiatry 1991;48851- 855PubMedGoogle ScholarCrossref
35.
Kane  JMMarder  SRSchooler  NRWirshing  WCUmbricht  DBaker  RWWirshing  DASafferman  AGanguli  RMcMeniman  MBorenstein  M Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.  Arch Gen Psychiatry 2001;58965- 972PubMedGoogle ScholarCrossref
36.
Wirz-Justice  AVan den Hoofdakker  RH Sleep deprivation in depression: what do we know, where do we go?  Biol Psychiatry 1999;46445- 453PubMedGoogle ScholarCrossref
37.
Husain  MMRush  AJFink  MKnapp  RPetrides  GRummans  TBiggs  MMO'Connor  KRasmussen  KLitle  MZhao  WBernstein  HJSmith  GMueller  MMcClintock  SMBailine  SHKellner  CH Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report.  J Clin Psychiatry 2004;65485- 491PubMedGoogle ScholarCrossref
38.
Marangell  LBGeorge  MSCallahan  AMKetter  TAPazzaglia  PJL'Herrou  TALeverich  GSPost  RM Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients.  Arch Gen Psychiatry 1997;54214- 222PubMedGoogle ScholarCrossref
39.
DeBattista  CPosener  JAKalehzan  BMSchatzberg  AF Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study.  Am J Psychiatry 2000;1571334- 1337PubMedGoogle ScholarCrossref
40.
Entsuah  ARHuang  HThase  ME Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.  J Clin Psychiatry 2001;62869- 877PubMedGoogle ScholarCrossref
41.
Thase  MEHaight  BRRichard  NRockett  CBMitton  MModell  JGVanMeter  SHarriett  AEWang  Y Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.  J Clin Psychiatry 2005;66974- 981PubMedGoogle ScholarCrossref
42.
Zarate  CAJSingh  JQuiroz  JDe Jesus  GDenicoff  KKLuckenbaugh  DAManji  HKCharney  DS A double-blind placebo-controlled study of memantine in major depression.  Am J Psychiatry 2006;163153- 155PubMedGoogle ScholarCrossref
43.
Bolshakov  KVGmiro  VETikhonov  DBMagazanik  LG Determinants of trapping block of N-methyl-D-aspartate receptor channels.  J Neurochem 2003;8756- 65PubMedGoogle ScholarCrossref
44.
Narita  MYoshizawa  KNomura  MAoki  KSuzuki  T Role of the NMDA receptor subunit in the expression of the discriminative stimulus effect induced by ketamine.  Eur J Pharmacol 2001;42341- 46PubMedGoogle ScholarCrossref
45.
De Vry  JJentzsch  KR Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine.  Behav Pharmacol 2003;14229- 235PubMedGoogle ScholarCrossref
46.
Maler  JMEsselmann  HWiltfang  JKunz  NLewczuk  PReulbach  UBleich  SRuther  EKornhuber  J Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons.  Brain Res 2005;1052156- 162PubMedGoogle ScholarCrossref
47.
White  PFSchuttler  JShafer  AStanski  DRHorai  YTrevor  AJ Comparative pharmacology of the ketamine isomers: studies in volunteers.  Br J Anaesth 1985;57197- 203PubMedGoogle ScholarCrossref
48.
Newcomer  JWFarber  NBJevtovic-Todorovic  VSelke  GMelson  AKHershey  TCraft  SOlney  JW Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.  Neuropsychopharmacology 1999;20106- 118PubMedGoogle ScholarCrossref
49.
Anand  ACharney  DSOren  DABerman  RMHu  XSCappiello  AKrystal  JH Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.  Arch Gen Psychiatry 2000;57270- 276PubMedGoogle ScholarCrossref
50.
Krystal  JHKarper  LPSeibyl  JPFreeman  GKDelaney  RBremner  JDHeninger  GRBowers  MB  JrCharney  DS Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses.  Arch Gen Psychiatry 1994;51199- 214PubMedGoogle ScholarCrossref
51.
Krystal  JHPerry  EB  JrGueorguieva  RBelger  AMadonick  SHAbi-Dargham  ACooper  TBMacdougall  LAbi-Saab  WD'Souza  DC Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.  Arch Gen Psychiatry 2005;62985- 994PubMedGoogle ScholarCrossref
52.
Kapur  SSeeman  P Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor.  Biol Psychiatry 2001;49954- 957PubMedGoogle ScholarCrossref
53.
Hustveit  OMaurset  AOye  I Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors.  Pharmacol Toxicol 1995;77355- 359PubMedGoogle ScholarCrossref
54.
Smith  DJAzzaro  AJZaldivar  SBPalmer  SLee  HS Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines.  Neuropharmacology 1981;20391- 396PubMedGoogle ScholarCrossref
55.
Lindefors  NBarati  SO'Connor  WT Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex.  Brain Res 1997;759205- 212PubMedGoogle ScholarCrossref
56.
Elliott  KKest  BMan  AKao  BInturrisi  CE N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development.  Neuropsychopharmacology 1995;13347- 356PubMedGoogle ScholarCrossref
57.
Byrd  LDStandish  LJHowell  LL Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs.  Eur J Pharmacol 1987;144331- 341PubMedGoogle ScholarCrossref
58.
Rothman  S Noncompetitive N-methyl-D-aspartate antagonists affect multiple ionic currents.  J Pharmacol Exp Ther 1988;246137- 142PubMedGoogle Scholar
59.
Wang  CXShuaib  A NMDA/NR2B selective antagonists in the treatment of ischemic brain injury.  Curr Drug Targets CNS Neurol Disord 2005;4143- 151PubMedGoogle ScholarCrossref
Original Article
August 2006

A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression

Author Affiliations

Author Affiliations: Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, Md.

Arch Gen Psychiatry. 2006;63(8):856-864. doi:10.1001/archpsyc.63.8.856
Abstract

Context  Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of antidepressant effects within a few days and that are sustained would have an enormous impact on patient care. Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders.

Objective  To determine whether a rapid antidepressant effect can be achieved with an antagonist at the N-methyl-D-aspartate receptor in subjects with major depression.

Design  A randomized, placebo-controlled, double-blind crossover study from November 2004 to September 2005.

Setting  Mood Disorders Research Unit at the National Institute of Mental Health.

Patients  Eighteen subjects with DSM-IV major depression (treatment resistant).

Interventions  After a 2-week drug-free period, subjects were given an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days, a week apart. Subjects were rated at baseline and at 40, 80, 110, and 230 minutes and 1, 2, 3, and 7 days postinfusion.

Main Outcome Measure  Changes in scores on the primary efficacy measure, the 21-item Hamilton Depression Rating Scale.

Results  Subjects receiving ketamine showed significant improvement in depression compared with subjects receiving placebo within 110 minutes after injection, which remained significant throughout the following week. The effect size for the drug difference was very large (d = 1.46 [95% confidence interval, 0.91-2.01]) after 24 hours and moderate to large (d = 0.68 [95% confidence interval, 0.13-1.23]) after 1 week. Of the 17 subjects treated with ketamine, 71% met response and 29% met remission criteria the day following ketamine infusion. Thirty-five percent of subjects maintained response for at least 1 week.

Conclusions  Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.

Trial Registration  clinicaltrials.gov Identifier: NCT00088699.

×